The article discusses three basic trends working against the ethical drug industry. A background on its prosperity is provided with returns of 20 percent to 30 percent and more on stockholders' equity. The fruits of the great research breakthroughs have reportedly been largely harvested. Tougher regulations by the U.S. Food & Drug Administration are attributed to public criticism of high-cost drugs and public reaction to the thalidomide tragedy. The prospect of serious competition is presented.
Processing Request
No Comments.